Immunovant/$IMVT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Immunovant

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Ticker

$IMVT
Sector
Primary listing

Employees

362

Immunovant Metrics

BasicAdvanced
$2.9B
-
-$2.84
0.66
-

What the Analysts think about Immunovant

Analyst ratings (Buy, Hold, Sell) for Immunovant stock.

Bulls say / Bears say

Robust cash runway—As of June 30, 2025, Immunovant held around $598.9 million in cash and equivalents, enough to fund announced clinical programs until the expected Graves’ disease readout in 2027.
Positive clinical proof points—Recent batoclimab studies achieved their primary endpoint in myasthenia gravis (showing MG-ADL improvements of 5.6 and 4.7 points at week 12), and delivered an 84% responder rate in CIDP for IgG reductions above 70%, validating the FcRn inhibition strategy and supporting registrational trials for IMVT-1402.
Strengthened balance sheet—A successful $450 million private placement at $20 per share in January 2025 added meaningful, non-dilutive capital for advancing the pipeline and maintaining operational flexibility.
High cash burn and mounting losses—Immunovant reported a fiscal 2025 net loss of $413.8 million and first quarter R&D expenses of $101.2 million, highlighting a rapid burn rate that could require additional equity dilution.
Strategic narrowing of lead asset—Leadership changes in April 2025 were accompanied by cutting IMVT-1402 target indications from ten to six, raising questions about execution and potentially shrinking future market opportunities.
Lost near-term commercialization path—Despite successful Phase 3 results with batoclimab in myasthenia gravis and CIDP, Immunovant will not pursue approval, passing up immediate revenue and shifting full commercial hopes to the still-experimental IMVT-1402.
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.

Immunovant Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Immunovant Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IMVT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs